Superior Tumor Detection for 68 Ga-FAPI-46 Versus 18 F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma
Journal of Nuclear Medicine · 2023-07 · 64 (7) · 1049-1055
DOI: 10.2967/jnumed.122.265215 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 06.04.2023. Verfasst von Kim M Pabst und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany; kim.pabst@uk-essen.de. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Quinolines, Bile Duct Neoplasms. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Management of cholangiocarcinoma is among other factors critically determined by accurate staging. Here, we aimed to assess the accuracy of PET/CT with the novel cancer fibroblast-directed 68Ga-fibroblast activation protein (FAP) inhibitor (FAPI)-46 tracer for cholangiocarcinoma staging and management guidance.
Methods
Patients with cholangiocarcinoma from a prospective observational trial were analyzed. 68Ga-FAPI-46 PET/CT detection efficacy was compared with 18F-FDG PET/CT and conventional CT. SUVmax/tumor-to-background ratio (Wilcoxon test) and separately uptake for tumor grade and location (Mann-Whitney U test) were compared. Immunohistochemical FAP and glucose transporter 1 (GLUT1) expression of stromal and cancer cells was analyzed. The impact on therapy management was investigated by pre- and post-PET/CT questionnaires sent to the treating physicians.
Results
In total, 10 patients (6 with intrahepatic cholangiocarcinoma and 4 with extrahepatic cholangiocarcinoma; 6 with grade 2 tumor and 4 with grade 3 tumor) underwent 68Ga-FAPI-46 PET/CT and conventional CT; 9 patients underwent additional 18F-FDG PET/CT. Immunohistochemical analysis was performed on the entire central tumor plain in 6 patients. Completed questionnaires were returned in 8 cases. Detection rates for 68Ga-FAPI-46 PET/CT, 18F-FDG PET/CT, and CT were 5, 5, and 5, respectively, for primary tumor; 11, 10, and 3, respectively, for lymph nodes; and 6, 4, and 2, respectively, for distant metastases. 68Ga-FAPI-46 versus 18F-FDG PET/CT SUVmax for primary tumor, lymph nodes, and distant metastases was 14.5 versus 5.2 (P = 0.043), 4.7 versus 6.7 (P = 0.05), and 9.5 versus 5.3 (P = 0.046), respectively, and tumor-to-background ratio (liver) was 12.1 versus 1.9 (P = 0.043) for primary tumor. Grade 3 tumors demonstrated a significantly higher 68Ga-FAPI-46 uptake than grade 2 tumors (SUVmax, 12.6 vs. 6.4; P = 0.009). Immunohistochemical FAP expression was high on tumor stroma (∼90% of cells positive), whereas GLUT1 expression was high on tumor cells (∼80% of cells positive). Overall, average expression intensity was estimated as grade 3 for FAP and grade 2 for GLUT1. Positive 68Ga-FAPI-46 PET findings led to a consequent biopsy workup and diagnosis of cholangiocarcinoma in 1 patient. However, patient treatment was not adjusted on the basis of 68Ga-FAPI-46 PET.
Conclusion
68Ga-FAPI-46 demonstrated superior radiotracer uptake, especially in grade 3 tumors, and lesion detection in patients with cholangiocarcinoma. In line with this result, immunohistochemistry demonstrated high FAP expression on tumor stroma. Accuracy is under investigation in an ongoing investigator-initiated trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany; kim.pabst@uk-essen.de.
- German Cancer Consortium, partner site University Hospital Essen, Essen, Germany.
- Division of Solid Tumor Translational Oncology, German Cancer Research Center, Heidelberg, Germany.
- Institute of Pathology, School of Medicine, Technical University of Munich, Munich, Germany.
- Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany.
- Department of Diagnostic and Interventional Radiology, University Hospital Essen, University of Duisburg-Essen, Essen Germany.
Zitieren
APA
Pabst, K. M., Trajkovic-Arsic, M., Cheung, P. F. Y., Ballke, S., Steiger, K., Bartel, T., Schaarschmidt, B. M., Milosevic, A., Seifert, R., Nader, M., Kessler, L., Siveke, J. T., Lueckerath, K., Kasper, S., Herrmann, K., Hirmas, N., Schmidt, H. H., Hamacher, R., & Fendler, W. P. (2023). Superior Tumor Detection for 68 Ga-FAPI-46 Versus 18 F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma. Journal of Nuclear Medicine, 64(7), 1049-1055. https://doi.org/10.2967/jnumed.122.265215
Vancouver
Pabst KM, Trajkovic-Arsic M, Cheung PFY, Ballke S, Steiger K, Bartel T, et al. Superior Tumor Detection for 68 Ga-FAPI-46 Versus 18 F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma. Journal of Nuclear Medicine. 2023;64(7):1049-1055. doi:10.2967/jnumed.122.265215
BibTeX
@article{Pabst2023,
author = {Pabst, Kim M and Trajkovic-Arsic, Marija and Cheung, Phyllis F Y and Ballke, Simone and Steiger, Katja and Bartel, Timo and Schaarschmidt, Benedikt M and Milosevic, Aleksandar and Seifert, Robert and Nader, Michael and Kessler, Lukas and Siveke, Jens T and Lueckerath, Katharina and Kasper, Stefan and Herrmann, Ken and Hirmas, Nader and Schmidt, Hartmut H and Hamacher, Rainer and Fendler, Wolfgang P},
title = {Superior Tumor Detection for 68 Ga-FAPI-46 Versus 18 F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma},
journal = {Journal of Nuclear Medicine},
year = {2023},
volume = {64},
number = {7},
pages = {1049--1055},
doi = {10.2967/jnumed.122.265215}
}
EUVIMED